A Phase IIa, Multicenter, Randomized, Placebo- and Active-Comparator Controlled,Cross-Over Clinical Trial to Study the Safety and Efficacy of MK-3577 in Patients withType 2 Diabetes Mellitus Who Have Inadequate Glycemic Control - A Study of the Safety and Efficacy of MK-3577 in Patients with Type 2 Diabetes Mellitus.
- Conditions
- Type 2 Diabetes MellitusMedDRA version: 9.1Level: LLTClassification code 10012601Term: Diabetes mellitus
- Registration Number
- EUCTR2009-009517-18-HU
- Lead Sponsor
- Merck and Co. Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 241
Inclusion Criteria
T2DM patients aged 18-70 years who are either drug naïve (AIC range of 6.5-9.5%) or on oral AHA monotherapy or low-dose combination therapy (AIC range of 6.0-9.0%)
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
No treatment with PPAR-? agonists (TZDs) or statins within 12 weeks
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method